Merck’s Welireg-lenvatinib combination wins EU panel backing for advanced kidney cancer
MRK•Merck’s Welireg-lenvatinib combination received a positive EU panel opinion for advanced clear cell kidney cancer after PD-1/PD-L1 inhibitor treatment. It reduced the risk of disease progression or death by 26% versus cabozantinib, while overall survival improvement was not statistically significant.
1. EU panel recommendation
The European Medicines Agency’s CHMP issued a positive opinion for Merck’s Welireg with lenvatinib in advanced clear cell kidney cancer following PD-1/PD-L1 inhibitor treatment. A European Commission decision on marketing authorization is expected within two months.
2. Trial results
The combination reduced the risk of disease progression or death by 26% versus cabozantinib. The improvement in overall survival was not statistically significant.
